# ANIP catalysts: ANI PHARMACEUTICALS INC PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/anip/catalysts

> ANI PHARMACEUTICALS INC (ANIP) has no upcoming catalysts in this calendar. The latest recorded is the ANI PHARMACEUTICALS INC earnings report, November 5, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, half-year only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | ANI PHARMACEUTICALS INC |
| Ticker | ANIP (Nasdaq) |
| SEC CIK | 1023024 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/anip |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Jan 2022 | [Corticotropin label expansion decision](https://sec-api.dev/pdufa/corticotropin) | ANIP |  | completed, approved | "received FDA approval for sNDA with expected Q2 2025 launch Launched January 2022" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1023024/000102302425000018/a250311anipleerinkconfer.htm)) |
| 1H 2025 | [ANI PHARMACEUTICALS INC interim data readout](https://sec-api.dev/companies/anip/catalysts) | ANIP |  | scheduled | "We expect to share the preliminary topline results of the SYNCHRONICITY clinical trial data in the first half of 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1023024/000102302425000015/anip-20241231.htm)) |
| February 28, 2025 | [ANI PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/anip/catalysts) | ANIP |  | completed | "ANI Pharmaceuticals Reports Record Fourth Quarter and Full-Year 2024 Financial Results and Raises 2025 Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1023024/000102302425000012/anip-20250228xexx991.htm)) |
| March 14, 2025 | [Fluocinolone label expansion decision](https://sec-api.dev/pdufa/fluocinolone) | ANIP | chronic non-infectious uveitis affecting the posterior segment of the eye | completed, approved | "On March 14, 2025, ANI Pharmaceuticals, Inc., issued a press release announcing that the U.S. Food and Drug Administration has approved an expanded label for ILUVIEN® (fluocinolone acetonide intravitreal implant) that includes an indication for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1023024/000102302425000021/ani-20250314.htm)) |
| Q2 2025 | [Corticotropin topline data readout](https://sec-api.dev/pdufa/corticotropin) | ANIP |  | scheduled | "Topline data expected in the second quarter of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1023024/000102302425000018/a250311anipleerinkconfer.htm)) |
| May 9, 2025 | [ANI PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/anip/catalysts) | ANIP |  | completed | "ANI Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Raises 2025 Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1023024/000102302425000044/anip-20250509xexx991.htm)) |
| Jun 2025 | [ANI PHARMACEUTICALS INC FDA approval](https://sec-api.dev/companies/anip/catalysts) | ANIP |  | completed, approved | "ANI received FDA approval to add the NIU-PS indication to ILUVIEN in the U.S. and transitioned commercialization efforts for ILUVIEN and YUTIQ to one brand, ILUVIEN, in the U.S. in June 2025. 2." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1023024/000102302425000110/anip-novembercorporatepr.htm)) |
| August 8, 2025 | [ANI PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/anip/catalysts) | ANIP |  | completed | "ANI Pharmaceuticals Reports Record Second Quarter 2025 Financial Results and Raises 2025 Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1023024/000102302425000081/anip-20250808xexx991.htm)) |
| November 7, 2025 | [ANI PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/anip/catalysts) | ANIP |  | completed | "ANI Pharmaceuticals Reports Record Third Quarter 2025 Financial Results and Raises 2025 Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1023024/000102302425000107/anip-20251107xexx991.htm)) |
| Q1 2026 | [Corticotropin topline data readout](https://sec-api.dev/pdufa/corticotropin) | ANIP |  | scheduled | "Topline data readout expected in Q1 2026 1." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1023024/000102302425000058/a250604anipjefferiesconf.htm)) |
| January 12, 2026 | [ANI PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/anip/catalysts) | ANIP |  | completed | "PRINCETON, N.J., Jan. 12, 2026 -- ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (Nasdaq: ANIP) today announced preliminary select financial results for full year 2025, provided full year 2026 financial guidance, and outlined its strategic priorities for continued growth." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1023024/000102302426000005/anip-20260112xexx991.htm)) |
| February 27, 2026 | [ANI PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/anip/catalysts) | ANIP |  | completed | "ANI Pharmaceuticals Reports Record Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Financial Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1023024/000102302426000013/anip-20260227xexx991.htm)) |
| May 8, 2026 | [ANI PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/anip/catalysts) | ANIP |  | completed | "ANI Pharmaceuticals Reports First Quarter 2026 Financial Results and Raises 2026 Financial Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1023024/000102302426000049/anip-20260508xexx991.htm)) |
| August 7, 2026 | [ANI PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/anip/catalysts) | ANIP |  | completed | "ANI Pharmaceuticals Reports Record Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1023024/000102302426000068/anip-20260807xexx991.htm)) |
| November 5, 2026 | [ANI PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/anip/catalysts) | ANIP |  | completed | "ANI Pharmaceuticals Reports Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1023024/000102302426000077/anip-20261105xexx991.htm)) |

## Drugs

- [Corticotropin](https://sec-api.dev/pdufa/corticotropin): 
- [Fluocinolone](https://sec-api.dev/pdufa/fluocinolone): chronic non-infectious uveitis affecting the posterior segment of the eye

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/anip/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "ANIP catalysts: ANI PHARMACEUTICALS INC PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/anip/catalysts

```bibtex
@misc{secapidev_companies_anip_catalysts_20261116,
  title        = {ANIP catalysts: ANI PHARMACEUTICALS INC PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/anip/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_anip_catalysts_20261116","title":"ANIP catalysts: ANI PHARMACEUTICALS INC PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/anip/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
